Humulina 30:70

Humulina 30:70 is a premixed injectable solution containing recombinant human insulin (rDNA) in a 30:70 proportion of protamine‑crystallized insulin to soluble insulin. It is supplied as a prescription‑only product for subcutaneous or intramuscular administration. The formulation is marketed in the European Union and belongs to the insulin class of antidiabetic agents. It is used to provide basal and prandial glucose control in patients with diabetes mellitus.

Humulina 30:70 is prescribed to help control hyperglycemia in adult patients with diabetes mellitus.

- Type 1 diabetes mellitus requiring basal and mealtime insulin coverage. - Type 2 diabetes mellitus when oral agents and lifestyle measures are insufficient. - As part of an individualized insulin regimen combined with diet and exercise. - Situations where a fixed ratio of intermediate‑acting and rapid‑acting insulin is preferred. - Transition periods when patients need both basal and prandial insulin in a single injection.

Adverse reactions to Humulina 30:70 are generally related to its insulin activity and formulation components.

Common: - Hypoglycemia, especially if meals are delayed or carbohydrate intake is reduced. - Injection site reactions such as redness, swelling, or itching. - Lipodystrophy, including lipoatrophy or lipohypertrophy at repeated injection sites. - Weight gain associated with improved glycemic control.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions ranging from urticaria to anaphylaxis. - Insulin edema or fluid retention causing peripheral swelling.

Clinicians should consider several precautions when prescribing Humulina 30:70 to ensure safe and effective use.

- Assess renal and hepatic function, as impairment can prolong insulin action. - Adjust doses during periods of illness, stress, or changes in physical activity. - Monitor blood glucose closely when initiating therapy or changing the dose. - Educate patients on proper injection technique and site rotation to reduce lipodystrophy. - Review concomitant medications that may mask hypoglycemia symptoms. - Use caution in pregnant or breastfeeding women; data are limited. - Avoid use in patients with known hypersensitivity to human insulin or protamine.

Humulina 30:70 may interact with other drugs, affecting glucose levels or insulin pharmacokinetics.

Avoid: - Beta‑blockers that can mask hypoglycemia symptoms. - High‑dose corticosteroids that significantly raise blood glucose. - MAO‑inhibitors combined with sympathomimetic agents causing unpredictable glycemic response.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - Thiazide diuretics that may elevate blood glucose. - ACE inhibitors and ARBs, which can potentiate insulin sensitivity. - Alcohol, especially in excess, as it can cause delayed hypoglycemia.